Design Therapeutics, Inc.
DSGN
$10.30
-$0.74-6.70%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 13.43M | 14.59M | 15.74M | 15.38M | 12.16M |
| Gross Profit | -13.43M | -14.59M | -15.74M | -15.38M | -12.16M |
| SG&A Expenses | 4.74M | 4.72M | 5.83M | 5.04M | 4.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.17M | 19.31M | 21.57M | 20.42M | 16.69M |
| Operating Income | -18.17M | -19.31M | -21.57M | -20.42M | -16.69M |
| Income Before Tax | -16.00M | -17.00M | -19.08M | -17.72M | -13.65M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.00M | -17.00M | -19.08M | -17.72M | -13.65M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.00M | -17.00M | -19.08M | -17.72M | -13.65M |
| EBIT | -18.17M | -19.31M | -21.57M | -20.42M | -16.69M |
| EBITDA | -18.01M | -19.16M | -21.42M | -20.26M | -16.55M |
| EPS Basic | -0.27 | -0.30 | -0.34 | -0.31 | -0.24 |
| Normalized Basic EPS | -0.17 | -0.19 | -0.21 | -0.20 | -0.15 |
| EPS Diluted | -0.27 | -0.30 | -0.34 | -0.31 | -0.24 |
| Normalized Diluted EPS | -0.17 | -0.19 | -0.21 | -0.20 | -0.15 |
| Average Basic Shares Outstanding | 58.74M | 56.95M | 56.86M | 56.76M | 56.68M |
| Average Diluted Shares Outstanding | 58.74M | 56.95M | 56.86M | 56.76M | 56.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |